Larry Tsai
No más puestos en curso
Perfil
Larry Tsai worked as Vice President-Research & Development at Aeris Therapeutics LLC from 2002 to 2011.
He then worked as Chief Medical Officer at Tetraphase Pharmaceuticals, Inc. from 2018 to 2019.
Tsai received his undergraduate degree from Stanford University and his doctorate degree from Massachusetts Institute of Technology.
Antiguos cargos conocidos de Larry Tsai.
| Empresas | Cargo | Fin |
|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 24/06/2019 |
Aeris Therapeutics LLC
 Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Director Técnico/Científico/I+D | 01/01/2011 |
Formación de Larry Tsai.
| Stanford University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Aeris Therapeutics LLC
Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Larry Tsai